Share class: Novartis AG

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A12,189,930,4971,909,335,641 ( 87.19 %) 190,660,464 ( 8.706 %) 87.19 %

Major shareholders: Novartis AG

NameEquities%Valuation
Novartis AG
6.625 %
145,083,991 6.625 % 15 738 M CHF
Sandoz Family Foundation
4.070 %
89,135,960 4.070 % 9 669 M CHF
UBS Asset Management Switzerland AG
3.123 %
68,391,910 3.123 % 7 419 M CHF
State Street Global Advisors Ltd.
0.2145 %
4,696,568 0.2145 % 509 M CHF
MFS International Singapore Pte Ltd.
0.2010 %
4,402,147 0.2010 % 478 M CHF
Credit Suisse AG
0.1548 %
3,390,433 0.1548 % 368 M CHF
Sjunde AP-fonden
0.1441 %
3,155,862 0.1441 % 342 M CHF
Eleva Capital SAS
0.1164 %
2,549,753 0.1164 % 277 M CHF
Amundi Asset Management SA (Investment Management)
0.1102 %
2,414,264 0.1102 % 262 M CHF
DWS CH AG
0.0957 %
2,096,766 0.0957 % 227 M CHF
░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
NameEquities%Valuation
Dodge & Cox
0.5581 %
12,221,876 0.5581 % 1 325 M CHF
PRIMECAP Management Co.
0.5483 %
12,008,055 0.5483 % 1 302 M CHF
DFA Australia Ltd.
0.3508 %
7,681,951 0.3508 % 833 M CHF
Eaton Vance Management
0.3190 %
6,984,872 0.3190 % 757 M CHF
Loomis, Sayles & Co. LP
0.2635 %
5,769,638 0.2635 % 625 M CHF
U.S. Trust Company of Delaware
0.2271 %
4,973,343 0.2271 % 539 M CHF
Fiduciary Trust Company International
0.1999 %
4,377,042 0.1999 % 474 M CHF
Wellington Trust Co., NA
0.1826 %
3,999,175 0.1826 % 434 M CHF
Wells Fargo Bank NA
0.1631 %
3,570,687 0.1631 % 387 M CHF
The Ayco Co. LP
0.1592 %
3,486,231 0.1592 % 378 M CHF
░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
NameEquities%Valuation
MFS International (UK) Ltd.
-
2,572,907 - 280 M CHF
LUKB Expert Fondsleitung AG
-
82,294 - 9 M CHF
Swiss Rock Asset Management AG
-
19,614 - 2 M CHF
N.F.U. Mutual Unit Managers Ltd.
-
18,420 - 2 M CHF
Skyblue Fund Managers (Pty) Ltd.
-
6,000 - 652 041 CHF

Breakdown by shareholder type

Institutional7.04%
Novartis AG6.63%
Other4.07%
Individuals0.08%
Unknown82.18%

Based on 1000 largest holdings

Geographical origin of shareholders

Switzerland 15.16%
United Kingdom 0.43%
France 0.35%
Singapore 0.21%
Sweden 0.20%
Ireland 0.17%
Germany 0.17%
Italy 0.15%
Belgium 0.12%
Norway 0.10%
Luxembourg 0.10%
Spain 0.08%
Individuals 0.08%
Denmark 0.07%
Liechtenstein 0.07%
Finland 0.05%
Australia 0.05%
Canada 0.05%
Austria 0.04%
United States 0.04%
Netherlands 0.03%
Japan 0.02%
New Zealand 0.02%
Cyprus 0.01%
Hong Kong 0.01%
South Africa 0.01%
Slovenia 0.01%

Based on 1000 largest holdings

Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Employees
76,057
More about the company
Exceptional Extension | BLACK FRIDAY -40% : Unlock Tomorrow's Top Investments with Our Exclusive Subscriber-Only Tools!
d
:
:
BENEFIT NOW